Literature DB >> 3608761

Correlation between ERG oscillatory potential and psychophysical contrast sensitivity in diabetes.

K Kawasaki, K Yonemura, Y Yokogawa, N Saito, S Kawakita.   

Abstract

Correlation between the electroretinographic oscillatory potential and psychophysical contrast sensitivity function was examined in patients with different stages of diabetic retinopathy. Contrast sensitivity function was evaluated by Arden's grating test. The amplitude of the oscillatory potential was significantly reduced in cases with low contrast sensitivity (P less than 0.01).

Entities:  

Mesh：

Year:  1986        PMID： 3608761     DOI： 10.1007/bf00159995

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN： 0012-4486            Impact factor:   2.379


  16 in total

1.  Electroretinogram in diabetic retinopathy.

Authors:  D YONEMURA; T AOKI; K TSUZUKI
Journal:  Arch Ophthalmol       Date:  1962-07

2.  Ocular aspects of diabetes.

Authors:  G I SCOTT
Journal:  Trans Ophthalmol Soc U K       Date:  1957

3.  Diabetic retinopathy viewed as a neurosensory disorder.

Authors:  G H Bresnick
Journal:  Arch Ophthalmol       Date:  1986-07

Review 4.  The importance of measuring contrast sensitivity in cases of visual disturbance.

Authors:  G B Arden
Journal:  Br J Ophthalmol       Date:  1978-04       Impact factor: 4.638

5.  The diagnostic value of the oscillatory potentials of the ERG and fluorescein angiography in diabetic proliferative retinopathy.

Authors:  P Algvere; M Gjötterberg
Journal:  Ophthalmologica       Date:  1974       Impact factor: 3.250

6.  The value of the oscillatory potential in selecting juvenile diabetics at risk of developing proliferative retinopathy.

Authors:  S E Simonsen
Journal:  Metab Pediatr Ophthalmol       Date:  1981

7.  Transactions of the Danish Ophthalmological Society September 1964--December 1964.

Authors:  E Gregersen
Journal:  Acta Ophthalmol (Copenh)       Date:  1965

8.  Contrast sensitivity in diabetics with and without background retinopathy.

Authors:  S Sokol; A Moskowitz; B Skarf; R Evans; M Molitch; B Senior
Journal:  Arch Ophthalmol       Date:  1985-01

9.  Contrast thresholds of diabetic patients determined by VECP and psychophysical measurements.

Authors:  H Yamazaki; E Adachi-Usami; J Chiba
Journal:  Acta Ophthalmol (Copenh)       Date:  1982-06

10.  Color vision defects in early diabetic retinopathy.

Authors:  M S Roy; R D Gunkel; M J Podgor
Journal:  Arch Ophthalmol       Date:  1986-02
View more
  6 in total

Review 1.  A multifocal electroretinogram model predicting the development of diabetic retinopathy.

Authors:  Marcus A Bearse; Anthony J Adams; Ying Han; Marilyn E Schneck; Jason Ng; Kevin Bronson-Castain; Shirin Barez
Journal:  Prog Retin Eye Res       Date:  2006-09-01       Impact factor: 21.198

2.  Steady-state pattern electroretinogram in insulin-dependent diabetics with no or minimal retinopathy.

Authors:  B Falsini; V Porciatti; G Scalia; S Caputo; A Minnella; M A Di Leo; G Ghirlanda
Journal:  Doc Ophthalmol       Date:  1989-10       Impact factor: 2.379

3.  Dopamine D1 receptor activation reduces local inner retinal inhibition to light-adapted levels.

Authors:  Reece E Mazade; Michael D Flood; Erika D Eggers
Journal:  J Neurophysiol       Date:  2019-02-06       Impact factor: 2.714

4.  Early visual deficits in streptozotocin-induced diabetic long evans rats.

Authors:  Moe H Aung; Moon K Kim; Darin E Olson; Peter M Thule; Machelle T Pardue
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-15       Impact factor: 4.799

5.  Loss of CD40 attenuates experimental diabetes-induced retinal inflammation but does not protect mice from electroretinogram defects.

Authors:  Ivy S Samuels; Jose-Andres C Portillo; Yanling Miao; Timothy S Kern; Carlos S Subauste
Journal:  Vis Neurosci       Date:  2017-01       Impact factor: 3.241

6.  Early Retinal Neuronal Dysfunction in Diabetic Mice: Reduced Light-Evoked Inhibition Increases Rod Pathway Signaling.

Authors:  Johnnie M Moore-Dotson; Jamie J Beckman; Reece E Mazade; Mrinalini Hoon; Adam S Bernstein; Melissa J Romero-Aleshire; Heddwen L Brooks; Erika D Eggers
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-03       Impact factor: 4.799
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.